title: Combined modality treatment with a weekly brief chemotherapy (ACOP-B) followed by locoregional radiotherapy in localized-stage intermediate- to high-grade non-Hodgkin's lymphoma.
abstract: BACKGROUND
  A cooperative study was undertaken to evaluate the efficacy and toxicity of a very brief course of chemotherapy followed by locoregional radiotherapy in patients with localized-stage intermediate- to high-grade non-Hodgkin's lymphoma (NHL).
  
  
  METHODS
  From January 1988 to November 1994, 84 patients with localized stages IA and IIA intermediate- to high-grade NHL underwent a combined modality treatment. All patients underwent a six-week chemotherapy regimen, ACOP-B (doxorubicin 50 mg/sqm and cyclophosphamide 350 mg/sqm on weeks 1, 3, 5; vincristine 1.4 mg/sqm and bleomycin 10 mg/sqm on weeks 2, 4, 6; prednisone 50 mg p.o. daily throughout the first two weeks and thereafter every other day), followed by locoregional radiotherapy (36 Gy).
  
  
  RESULTS
  The median age was 58 years, with 35% older than 65 years; 52 patients had stage I and 32 stage II; 39 patients had extranodal +/- nodal involvement, and 4 had testicular involvement. Treatment was well tolerated, with only 38% suffering from mild mucositis and no toxic deaths. Seventy-nine patients achieved CR after ACOP-B and 83 at the end of the program. With a median follow-up of four years, relapse-free survival was 79% with 15 relapses (93% disseminated). Two patients with testis lymphoma had CNS relapses. Overall survival was 90% at four years.
  
  
  CONCLUSIONS
  This combined program is effective and probably curative in localized stage intermediate- to high-grade NHL, with low toxicity, also in elderly people. Patients with NHL of the testis, as primary site, require CNS prophylaxis due to the high likelihood of CNS relapse.
authors.affiliation: Divisione di Ematologia, Azienda Ospedaliera S. Giovanni Battista, Torino, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Freilone
authors.forename: B
authors.initials: B
authors.lastname: Botto
authors.forename: U
authors.initials: U
authors.lastname: Vitolo
authors.forename: M
authors.initials: M
authors.lastname: Bertini
authors.forename: E
authors.initials: E
authors.lastname: Audisio
authors.forename: R
authors.initials: R
authors.lastname: Calvi
authors.forename: M
authors.initials: M
authors.lastname: Cucchi
authors.forename: A
authors.initials: A
authors.lastname: De Crescenzo
authors.forename: A
authors.initials: A
authors.lastname: Gallamini
authors.forename: R
authors.initials: R
authors.lastname: Ghio
authors.forename: L
authors.initials: L
authors.lastname: Griso
authors.forename: A
authors.initials: A
authors.lastname: Levis
authors.forename: G
authors.initials: G
authors.lastname: Massara
authors.forename: L
authors.initials: L
authors.lastname: Orsucci
authors.forename: U
authors.initials: U
authors.lastname: Ricardi
authors.forename: D
authors.initials: D
authors.lastname: Rota Scalabrini
authors.forename: F
authors.initials: F
authors.lastname: Salvi
authors.forename: V
authors.initials: V
authors.lastname: Secondo
authors.forename: L
authors.initials: L
authors.lastname: Resegotti
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011878:Radiotherapy / Q000009:adverse effects